乳腺前哨淋巴结活检技术-乳腺外科的又一个里程碑.pptVIP

* 美国乳腺与肠道外科辅助治疗研究组 NSABP B-32：是一项大型前瞻性Ⅲ期随机临床研究，主要评价前哨淋巴结活检术与腋窝淋巴结清扫术能否获得相同的局部控制率和总生存率。 入组条件:临床腋淋巴结阴性，可手术浸润性乳腺癌 是目前最大的试验 Background: NSABP B-32 is the largest prospective randomized phase III trial designed to determine in SN negative patients that SNR alone results in the same survival and regional control as SNR + AD while reducing morbidity. It was designed to detect a survival difference of 2% between the 2 groups at 5 years. Methods: 5,611 women with operable, clinically N0, invasive breast cancer were randomized to SNR + AD (Group 1) or to SNR alone with AD only if SNs were positive (G